Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 501–600 of 1,003
Wang, J.-Y., Huang, Y.-N., Chiu, C., Tweedie, D., Luo, W., Pick, C. G., Chou, S.-Y., Luo, Y., Hoffer, B. J., Greig, N. H., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0631-6 · Cited by 55
Nakayama, Y., Kosek, J., Capone, L., Hur, E. M., Schafer, P. H., & Ringheim, G. E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601725 · Cited by 54
Zhong, Y., Chi, F., Wu, H., Liu, Y., Xie, Z., Huang, W., Shi, W., & Qian, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114142 · Cited by 55
Michaelides, I. N., & Collie, G. W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01882 · Cited by 54
Toxicity Assessment of 7 Anticancer Compounds in Zebrafish
Gao, X.-P., Feng, F., Zhang, X., Liu, X.-X., Wang, Y.-B., She, J., He, Z.-H., & He, M.-F. (2014) · International Journal of Toxicology · doi:10.1177/1091581814523142 · Cited by 54
Davis, D. A., Mishra, S., Anagho, H. A., Aisabor, A. I., Shrestha, P., Wang, V., Takamatsu, Y., Maeda, K., Mitsuya, H., Zeldis, J. B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17960 · Cited by 54
Cermakova, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 48
Ligand Enabled Pd(II)-Catalyzed γ-C(sp3)–H Lactamization of Native Amides
Liu, S., Zhuang, Z., Qiao, J. X., Yeung, K., Su, S., Cherney, E. C., Ruan, Z., Ewing, W. R., Poss, M. A., & Yu, J. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c10183 · Cited by 54
Razumkov, H., Jiang, Z., Baek, K., You, I., Geng, Q., Donovan, K. A., Tang, M. T., Metivier, R. J., Mageed, N., Seo, P., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06127 · Cited by 53
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
Ruffilli, C., Röth, S., Rodrigo, M., Boyd, H., Zelcer, N., & Moreau, K. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00142 · Cited by 53
Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 53
Degraders upgraded: the rise of PROTACs in hematological malignancies
Casan, J. M. L., & Seymour, J. F. (2024) · Blood · doi:10.1182/blood.2023022993 · Cited by 53
Lupas, A. N., Zhu, H., & Korycinski, M. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004023 · Cited by 47
Rajadhyaksha, A. M., Ra, S., Kishinevsky, S., Lee, A. S., Romanienko, P. J., DuBoff, M. A., Yang, C., Zupan, B., Byrne, M. E., Daruwalla, Z., et al. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.09.039 · Cited by 53
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 53
Pulte, E. D., Dmytrijuk, A., Nie, L., Goldberg, K. B., McKee, A. E., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0440 · Cited by 51
USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Nguyen, T. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111391118 · Cited by 53
Liang, C., Yen, Y., Hung, L.-Y., Wang, S., Pu, C., Chien, H., Tsai, J., Lee, C., Yen, F., & Chen, Y. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.038 · Cited by 53
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Kagiou, C., Cisneros, J. A., Farnung, J., Liwocha, J., Offensperger, F., Dong, K. D., Yang, K., Tin, G., Horstmann, C. S., Hinterndorfer, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49739-3 · Cited by 53
Identification and validation of protein targets of bioactive small molecules
Titov, D. V., & Liu, J. O. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.070 · Cited by 52
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 52
Enantiomerization Mechanism of Thalidomide and the Role of Water and Hydroxide Ions
Tian, C., Xiu, P., Yan, M., Zhao, W., Wang, Z., & Zhou, R. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201202651 · Cited by 52
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Xia, L., Ba, M.-Y., Liu, W., Cheng, W., Hu, C.-P., Zhao, Q., Yao, Y., Sun, M., & Duan, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0159 · Cited by 52
Mechanisms of lenalidomide sensitivity and resistance
Martinez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 46
Chowdhury, G., Murayama, N., Okada, Y., Uno, Y., Shimizu, M., Shibata, N., Guengerich, F. P., & Yamazaki, H. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900367p · Cited by 47
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51
Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
Heim, C., Spring, A.-K., Kirchgäßner, S., Schwarzer, D., & Hartmann, M. D. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.001 · Cited by 51
Jain, D., Hodonsky, C. J., Schick, U. M., Morrison, J., Minnerath, S., Brown, L., Schurmann, C., Liu, Y., Auer, P. L., Laurie, C. A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx024 · Cited by 51
Yang, J., Huang, M. J., Zhou, L., He, X., Jiang, X., Zhang, Y., & Xu, G. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002246 · Cited by 51
Li, H., Zhang, Q., Li, W., Li, H., Bao, J., Yang, C., Wang, A., Wei, J., Chen, S., & Jin, H. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.04.016 · Cited by 51
Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 48
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology
Fan, F., & Podar, K. (2021) · Cancers · doi:10.3390/cancers13102326 · Cited by 51
The Flavonoid Apigenin Downregulates CDK1 by Directly Targeting Ribosomal Protein S9
Iizumi, Y., Oishi, M., Taniguchi, T., Goi, W., Sowa, Y., & Sakai, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073219 · Cited by 51
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
Yang, J., Terebelo, H. R., & Zonder, J. A. (2012) · Advances in Hematology · doi:10.1155/2012/801495 · Cited by 51
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Ichikawa, S., Payne, N. C., Xu, W., Chang, C., Vallavoju, N., Frome, S., Flaxman, H. A., Mazitschek, R., & Woo, C. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.003 · Cited by 51
Kumar, S., Venkatachalapathy, M., Sistla, R. K., & Poongavanam, V. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104205 · Cited by 50
Targeted protein degradation in the transmembrane and extracellular space
Zhu, R., Zhang, H., & Chen, P. R. (2025) · Science · doi:10.1126/science.adx5094 · Cited by 50
Multivalent Photoaffinity Probe for Labeling Small Molecule Binding Proteins
Li, G., Liu, Y., Yu, X., & Li, X. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500195w · Cited by 50
A Mental Retardation-linked Nonsense Mutation in Cereblon Is Rescued by Proteasome Inhibition
Xu, G., Jiang, X., & Jaffrey, S. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.472092 · Cited by 43
Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2
Ramachandran, S., Makukhin, N., Haubrich, K., Nagala, M., Forrester, B., Lynch, D. M., Casement, R., Testa, A., Bruno, E., Gitto, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41894-3 · Cited by 50
Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 49
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products
Chan, K. I., Zhang, S., Li, G., Xu, Y., Cui, L., Wang, Y., Su, H., Tan, W., & Zhong, Z. (2024) · Aging and Disease · doi:10.14336/ad.2023.0520 · Cited by 49
An orthogonalized PYR1-based CID module with reprogrammable ligand-binding specificity
Park, S., Qiu, J., Wei, S., Peterson, F. C., Beltrán, J., Medina‐Cucurella, A. V., Vaidya, A. S., Xing, Z., Volkman, B. F., Nusinow, D. A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01447-7 · Cited by 49
Improvement of the evaluation method for teratogenicity using zebrafish embryos
Yamashita, A., Inada, H., Chihara, K., Yamada, T., Deguchi, J., & Funabashi, H. (2014) · The Journal of Toxicological Sciences · doi:10.2131/jts.39.453 · Cited by 49
Immunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 49
Beedie, S., Rore, H. M., Barnett, S., Chau, C. H., Luo, W., Greig, N. H., Figg, W. D., & Vargesson, N. (2016) · Oncotarget · doi:10.18632/oncotarget.8909 · Cited by 49
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
North, B. J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S. S., & Quayle, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173507 · Cited by 49
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 49
Song, Y. Y., Park, P. M. C., Wu, L., Ray, A., Picaud, S., Li, D., Wimalasena, V. K., Du, T., Filippakopoulos, P., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0467-z · Cited by 49
Matyskiela, M. E., Zhu, J., Baughman, J. M., Clayton, T., Slade, M., Wong, H. K., Danga, K., Zheng, X., Labow, M., LeBrun, L., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00674 · Cited by 44
Carbonneau, S., Sharma, S. P., Peng, L., Rajan, V., Hainzl, D., Hénault, M., Yang, C., Hale, J. A., Shulok, J. R., Tallarico, J. A., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.012 · Cited by 49
Ligands for cereblon: 2017–2021 patent overview
Kazantsev, A., & Krasavin, M. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.1999415 · Cited by 49
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma
Auner, H. W., & Cenci, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13172 · Cited by 49
Deregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 48
An Overview of the Different Types of Catalysts in Organic Synthesis
Dias, F. R. F., Ferreira, V. F., & Cunha, A. C. (2012) · Revista Virtual de Química · doi:10.5935/1984-6835.20120060 · Cited by 48
Xu, Q., Hou, Y.-X., Langlais, P. R., Erickson, P. W., Zhu, J. J., Shi, C.-X., Luo, M., Zhu, Y., Xu, Y., Mandarino, L. J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2331-0 · Cited by 48
Momtaz, S., Memariani, Z., El‐Senduny, F. F., Sanadgol, N., Golab, F., Katebi, M., Abdolghaffari, A. H., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00361 · Cited by 48
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 44
From the Farm to the Lab: How Chicken Embryos Contribute to the Field of Teratology
Wachholz, G. E., Rengel, B. D., Vargesson, N., & Fraga, L. R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.666726 · Cited by 48
Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen
Zhang, S., Li, Y., Li, T., Zhang, Y., Li, H., Cheng, Z., Peng, N., Liu, Y., Xu, J., & He, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02037 · Cited by 48
Selectivity through Targeted Protein Degradation (TPD)
Gopalsamy, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00397 · Cited by 48
The evolution of our understanding of macrophages and translation of findings toward the clinic
Martínez, F. O., & Gordon, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.985658 · Cited by 48
Abalde‐Cela, S., Hermida‐Ramón, J. M., Contreras-Carballada, P., Cola, L. D., Guerrero‐Martínez, A., Álvarez‐Puebla, R. A., & Liz‐Marzán, L. M. (2010) · ChemPhysChem · doi:10.1002/cphc.201000800 · Cited by 48
Degradation of Akt using protein-catalyzed capture agents: DEGRADATION OF AKT USING PCC AGENTS
Henning, R. K., Varghese, J. O., Das, S., Nag, A., Tang, G., Tang, K., Sutherland, A. M., & Heath, J. R. (2016) · Journal of Peptide Science · doi:10.1002/psc.2858 · Cited by 45
Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
Kazuki, Y., Akita, M., Kobayashi, K., Osaki, M., Satoh, D., Ohta, R., Abe, S., Takehara, S., Kazuki, K., Yamazaki, H., et al. (2016) · Scientific Reports · doi:10.1038/srep21419 · Cited by 48
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 47
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives
Nowak, R. P., Che, J., Ferrao, S., Kong, N. R., Liu, H., Zerfas, B. L., & Jones, L. H. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00347c · Cited by 39
Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
Hao, B., Chen, K., Zhai, L., Liu, M., Liu, B., & Tan, M. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae019 · Cited by 47
Patil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 43
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 47
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 47
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 47
Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
Juan, A., Noblejas‐López, M. D. M., Arenas-Moreira, M., Alonso‐Moreno, C., & Ocaña, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805336 · Cited by 47
Prenatal exposure to environmental factors and congenital limb defects
Alexander, P. G., Clark, K. L., & Tuan, R. S. (2016) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21140 · Cited by 47
Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity
Sebastian, S., Zhu, Y. X., Braggio, E., Shi, C.-X., Panchabhai, S. C., Wier, S. A. V., Ahmann, G. J., Chesi, M., Bergsagel, P. L., Stewart, A. K., et al. (2016) · Blood · doi:10.1182/blood-2016-09-738872 · Cited by 47
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
PROTACS: A technology with a gold rush-like atmosphere
Wang, Y., Lan, L., Wang, M., Zhang, J., Gao, Y., Shi, L., & Sun, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115037 · Cited by 46
The application of PROTAC in HDAC
Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 46
The Recent Applications of Magnetic Nanoparticles in Biomedical Fields
Hong, J., Wang, L., Zheng, Q., Cai, C., Yang, X., & Liao, Z. (2024) · Materials · doi:10.3390/ma17122870 · Cited by 46
Identifizierung der Zielproteine bioaktiver Verbindungen: Die Suche nach der Nadel im Heuhaufen
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie · doi:10.1002/ange.201208749 · Cited by 46
Kang, J., Park, S., Jeong, S. P., Han, M., Lee, C., Lee, K. M., Kim, N., Song, M., Choi, M., Ye, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502166113 · Cited by 46
Busch, L., Mougiakakos, D., Büttner-Herold, M. J., Müller, M. J., Volmer, D. A., Bach, C., Fabri, M., Bittenbring, J. T., Neumann, F., Boxhammer, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0114-0 · Cited by 46
Kaur, G., & Silakari, O. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.05.014 · Cited by 46
Chung, C.-I., Zhang, Q., & Shu, X. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03476 · Cited by 47
Application of high-performance magnetic nanobeads to biological sensing devices
Kabe, Y., Sakamoto, S., Hatakeyama, M., Yamaguchi, Y., Suematsu, M., Itonaga, M., & Handa, H. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1548-y · Cited by 46
Self-citationIdentification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor-Ruiz, C., & Winter, G. E. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 41
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 46
Lee, C. J. J., Gonçalves, L. L., & Wells, P. G. (2011) · The FASEB Journal · doi:10.1096/fj.10-178814 · Cited by 43
A Trifluorinated Thiazoline Scaffold Leading to Pro‐apoptotic Agents Targeting Prohibitins
Pérez‐Perarnau, A., Preciado, S., Palmeri, C. M., Moncunill‐Massaguer, C., Iglesias‐Serret, D., González‐Gironès, D. M., Miguel, M., Karasawa, S., Sakamoto, S., Cosialls, A. M., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405758 · Cited by 46
Self-citationCereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Cieślak, M., & Słowianek, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030812 · Cited by 45
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 45
Drug Discovery Approaches to Target E3 Ligases
Rodríguez-Gimeno, A., & Galdeano, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400656 · Cited by 45
High-throughput ligand diversification to discover chemical inducers of proximity
Shaum, J. B., Ordoño, M. M. I., Steen, E. A., Wenge, D. V., Cheong, H., Janowski, J., Hunkeler, M., Bilotta, E. M., Rutter, Z. J., Barta, P. A., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02137-2 · Cited by 46
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 45
Role of RNF20 in cancer development and progression – a comprehensive review
Sethi, G., Shanmugam, M. K., Arfuso, F., & Kumar, A. P. (2018) · Bioscience Reports · doi:10.1042/bsr20171287 · Cited by 45
Nabavi, S. F., Atanasov, A. G., Khan, H. Z., Barreca, D., Trombetta, D., Testai, L., Sureda, A., Tejada, S., Vacca, R. A., Pittalà, V., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.018 · Cited by 45
Chen, D., Gehringer, M., & Lorenz, S. (2018) · ChemBioChem · doi:10.1002/cbic.201800321 · Cited by 45
Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells
Belluti, S., Orteca, G., Semeghini, V., Rigillo, G., Parenti, F., Ferrari, É., & Imbriano, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010028 · Cited by 45
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.